Penumbra, Inc. Reports First Quarter 2026 Financial Results
Rhea-AI Summary
Penumbra (NYSE: PEN) reported Q1 2026 revenue of $374.8 million, up 15.6% year-over-year, with thrombectomy revenue $253.9 million (+12.1%) and embolization & access $120.8 million (+23.8%). Gross margin was 67.6%. Operating expenses were $215.2 million (R&D $22.4M; SG&A $192.8M, including $9.4M acquisition-related expenses). Income from operations was $38.2 million and net income $32.6 million. Given the pending acquisition by Boston Scientific (NYSE: BSX), the company will not provide full-year 2026 guidance or host an earnings call.
AI-generated analysis. Not financial advice.
Positive
- Revenue +15.6% YoY to $374.8M
- Embolization & access +23.8% YoY to $120.8M
- Net income $32.6M in Q1 2026
Negative
- Company will not provide full-year 2026 guidance due to pending acquisition
- $9.4M acquisition-related expenses included in SG&A in Q1
News Market Reaction – PEN
On the day this news was published, PEN gained 0.14%, reflecting a mild positive market reaction. This price movement added approximately $18M to the company's valuation, bringing the market cap to $12.75B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Pre-news, PEN was down 0.24% while key peers showed mostly small moves; only PODD appeared in momentum scans, moving up about 1.3%, suggesting stock-specific dynamics rather than a broad devices move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 25 | Quarter & year results | Positive | -0.3% | Reported strong Q4 and FY2025 growth with margin expansion and solid profitability. |
| Feb 04 | Parent earnings | Positive | -4.5% | Boston Scientific posted robust Q4 and FY2025 sales and EPS with 2026 growth guidance. |
| Jan 15 | Preliminary results | Positive | +11.8% | Pre-announced Q4 and FY2025 revenue and margins ahead of formal results release. |
| Nov 05 | Quarterly results | Positive | +17.3% | Q3 2025 results showed strong revenue growth, high U.S. thrombectomy sales and raised guidance. |
| Jul 29 | Quarterly results | Positive | +11.9% | Q2 2025 revenue growth, strong U.S. thrombectomy and VTE trends, and higher 2025 guidance. |
Earnings and related financial updates have generally been received positively, with three strong upside reactions but two instances where solid results coincided with negative price moves.
Over the past year, Penumbra has repeatedly delivered double‑digit revenue growth, with Q2 2025 revenue at $339.5M, Q3 2025 at $354.7M, and Q4 2025 at $385.4M, alongside gross margins around the high‑60% range. Preliminary Q4 2025 figures and full 2025 results were followed by Boston Scientific’s agreement to acquire Penumbra at $374 per share. Today’s Q1 2026 earnings continue this pattern of profitable growth while the company operates under a pending acquisition.
Historical Comparison
Prior earnings and financial updates for PEN have produced average moves of about 7.25%, with mostly positive reactions but occasional downside despite strong results.
Earnings releases from Q2–Q4 2025 showed consistent revenue growth into the mid‑$300M range, improving gross margins near the high‑60% level, and repeated guidance increases. These financial trends set the backdrop for Boston Scientific’s proposed $374 per‑share acquisition and frame Q1 2026 results within a trajectory of scaling thrombectomy and embolization businesses under an agreed merger.
Market Pulse Summary
This announcement highlights continued double‑digit revenue growth, with Q1 2026 revenue of $374.8M, thrombectomy revenue of $253.9M, and gross margin of 67.6%. Operating income of $38.2M and net income of $32.6M underscore ongoing profitability. The company also recorded $9.4M of acquisition‑related expenses tied to the pending Boston Scientific transaction. Investors may watch future filings and merger milestones, along with segment growth in thrombectomy and embolization, to assess the evolving risk‑reward profile.
Key Terms
thrombectomy medical
embolization medical
AI-generated analysis. Not financial advice.
- Revenue of
$374 15.6% compared to the first quarter of 2025. - Global thrombectomy revenue of
$253 12.1% compared to the first quarter of 2025. - Global embolization and access revenue of
$120 23.8% compared to the first quarter of 2025. - Gross profit margin of
67.6% in the first quarter of 2026, an increase of1.0% compared to the first quarter of 2025. - Total operating expenses of
$215.2 million $22.4 million $192 $9.4 million - Income from operations of
$38 $32
Full Year 2026 Financial Outlook and Webcast and Conference Call Information
Given the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation (NYSE: BSX), the Company will not be providing financial guidance for the full year 2026 or hosting a conference call to discuss financial results for the three months ended March 31, 2026.
About Penumbra
Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn, and X.
Forward-Looking Statements
Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the risk that the pending acquisition by Boston Scientific Corporation will not be completed in the expected timeframe or at all, including the risk that required regulatory approvals will not be obtained; potential adverse effects to our business during the pendency of the acquisition, such as employee departures or diversion of management's attention from our business; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 25, 2026. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.
Penumbra, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands) | ||||
March 31, 2026 | December 31, 2025 | |||
Assets | ||||
Current assets: | ||||
Cash and cash equivalents | $ 241,289 | $ 186,897 | ||
Marketable investments | 374,371 | 357,919 | ||
Accounts receivable, net | 183,295 | 190,021 | ||
Inventories | 438,539 | 431,549 | ||
Prepaid expenses and other current assets | 37,912 | 50,298 | ||
Total current assets | 1,275,406 | 1,216,684 | ||
Property and equipment, net | 134,059 | 117,436 | ||
Operating lease right-of-use assets | 170,273 | 173,587 | ||
Finance lease right-of-use assets | 25,209 | 25,972 | ||
Intangible assets, net | 5,946 | 6,186 | ||
Goodwill | 166,589 | 166,750 | ||
Deferred taxes | 79,972 | 79,188 | ||
Other non-current assets | 40,984 | 40,716 | ||
Total assets | $ 1,898,438 | $ 1,826,519 | ||
Liabilities and Stockholders' Equity | ||||
Current liabilities: | ||||
Accounts payable | $ 43,658 | $ 34,736 | ||
Accrued liabilities | 151,543 | 132,163 | ||
Current operating lease liabilities | 14,144 | 13,841 | ||
Current finance lease liabilities | 2,386 | 2,393 | ||
Total current liabilities | 211,731 | 183,133 | ||
Non-current operating lease liabilities | 179,424 | 182,751 | ||
Non-current finance lease liabilities | 20,221 | 20,714 | ||
Other non-current liabilities | 13,250 | 12,318 | ||
Total liabilities | 424,626 | 398,916 | ||
Stockholders' equity: | ||||
Common stock | 39 | 39 | ||
Additional paid-in capital | 1,201,423 | 1,185,525 | ||
Accumulated other comprehensive income | 2,075 | 4,348 | ||
Retained earnings | 270,275 | 237,691 | ||
Total stockholders' equity | 1,473,812 | 1,427,603 | ||
Total liabilities and stockholders' equity | $ 1,898,438 | $ 1,826,519 | ||
Penumbra, Inc. Condensed Consolidated Statements of Operations (unaudited) (in thousands, except share and per share amounts) | ||||
Three Months Ended March 31, | ||||
2026 | 2025 | |||
Revenue | $ 374,758 | $ 324,140 | ||
Cost of revenue | 121,347 | 108,257 | ||
Gross profit | 253,411 | 215,883 | ||
Operating expenses: | ||||
Research and development | 22,382 | 22,077 | ||
Sales, general and administrative | 192,795 | 153,456 | ||
Total operating expenses | 215,177 | 175,533 | ||
Income from operations | 38,234 | 40,350 | ||
Interest and other income, net | 3,454 | 3,508 | ||
Income before income taxes | 41,688 | 43,858 | ||
Provision for income taxes | 9,104 | 4,635 | ||
Net income | $ 32,584 | $ 39,223 | ||
Net income per share: | ||||
Basic | $ 0.83 | $ 1.02 | ||
Diluted | $ 0.82 | $ 1.00 | ||
Weighted average shares outstanding: | ||||
Basic | 39,275,424 | 38,562,191 | ||
Diluted | 39,543,780 | 39,163,428 | ||
Penumbra, Inc. Reconciliation of Revenue Growth by Geographic Regions (unaudited) (in thousands, except for percentages) | ||||||||
Three Months Ended March 31, | Change | |||||||
2026 | 2025 | $ | % | |||||
$ 296,387 | $ 256,860 | $ 39,527 | 15.4 % | |||||
International | 78,371 | 67,280 | 11,091 | 16.5 % | ||||
Total | $ 374,758 | $ 324,140 | $ 50,618 | 15.6 % | ||||
Penumbra, Inc. Reconciliation of Revenue Growth by Product Categories (unaudited) (in thousands, except for percentages) | ||||||||
Three Months Ended March 31, | Change | |||||||
2026 | 2025 | $ | % | |||||
Thrombectomy | $ 253,917 | $ 226,544 | $ 27,373 | 12.1 % | ||||
Embolization and Access | 120,841 | 97,596 | 23,245 | 23.8 % | ||||
Total | $ 374,758 | $ 324,140 | $ 50,618 | 15.6 % | ||||
Investor Relations
Penumbra, Inc.
investors@penumbrainc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-reports-first-quarter-2026-financial-results-302764359.html
SOURCE Penumbra, Inc.